The Korean Journal of Nuclear Medicine (대한핵의학회지)

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

Updates in the Management of Coronary Artery Disease

관동맥질환 치료의 최신 지견

  • Yang, Dong-Heon (Division of Cardiology, Department of Internal Medicine, Kyungpook National University Medical School) ;
  • Chae, Shung-Chull (Division of Cardiology, Department of Internal Medicine, Kyungpook National University Medical School)
  • 양동헌 (경북대학교 의과대학 순환기내과) ;
  • 채성철 (경북대학교 의과대학 순환기내과)
  • Published : 2005.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Coronary artery disease (CAD) has been increasing during the last decade and is the one of major causes of death. The management of patients with coronary artery disease has evolved considerably. There are two main strategies in the management of CAD, complementary, not competitive, each other; the pharmacologic therapy to prevent and treat CAD and the percutaneous coronary Intervention (PCI) to restore coronary flow. Antiplatelet drugs and cholesterol lowering drugs have central roles in pharmacotherapy. Drug eluting stent (DES) bring about revolutional changes in PCI. In the management of patients with 57 segment elevation acute myocardial infarction (AMI), there has been a debate on the better strategy for the restoration of coronary flow. Thrombolytic therapy is widely available and easy to administer, whereas primary PCI is less available and more complex, but mote complete. Recently published evidences in the pharmacologic therapy including antiplatelet and stalin, and PCI including DES and reperfusion therapy in patients with ST segment elevation AMI were reviewed.

Keywords

References

  1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002;324:71-86 https://doi.org/10.1136/bmj.324.7329.71
  2. Eidelman RS, Hebert PR, Weisman SM, Hennekens CH. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 2003;163:2006-10 https://doi.org/10.1001/archinte.163.17.2006
  3. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-1304 https://doi.org/10.1056/NEJMoa050613
  4. Scrutinio D, Cimminiello C, Marubini E, Pitzalis MV, Di Biase M, Rizzon P, on behalf of the STAMI Group. Ticlopidine versus aspirin after myocardial infarction (STAMI) trial. J Am Coll Cardiol 2001;37:1259-65 https://doi.org/10.1016/S0735-1097(01)01164-0
  5. CAPRIE steering committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39 https://doi.org/10.1016/S0140-6736(96)09457-3
  6. The clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502 https://doi.org/10.1056/NEJMoa010746
  7. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, et al, for the CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. JAMA 2002;288:2411-20 https://doi.org/10.1001/jama.288.19.2411
  8. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al, for the Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCICURE study. Lancet 2001;358:527-33 https://doi.org/10.1016/S0140-6736(01)05701-4
  9. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, et al, for the CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-89 https://doi.org/10.1056/NEJMoa050522
  10. Serebruany VL, Midei MG, Malinin AI, Oshrine BR, Lowry DR, Sane DC, et al. Absence of interaction between atorvastatin or other statins and clopidogrel. Arch Intern Med 2004;164:2051-7 https://doi.org/10.1001/archinte.164.18.2051
  11. Heart Protection Study collaborative Group. MRC/BHF Heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22 https://doi.org/10.1016/S0140-6736(02)09327-3
  12. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al, for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504 https://doi.org/10.1056/NEJMoa040583
  13. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al, for the REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1071-80 https://doi.org/10.1001/jama.291.9.1071
  14. Larosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al, for the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35 https://doi.org/10.1056/NEJMoa050461
  15. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998-3007 https://doi.org/10.1001/jama.288.23.2998
  16. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al, for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58 https://doi.org/10.1016/S0140-6736(03)12948-0
  17. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al, for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 2004;110:227-39 https://doi.org/10.1161/01.CIR.0000133317.49796.0E
  18. Fattori R, Piva T. Drug-elution stents in vascular intervention. Lancet 2003;361:247-9 https://doi.org/10.1016/S0140-6736(03)12275-1
  19. Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001;103:192-5 https://doi.org/10.1161/01.CIR.103.2.192
  20. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al, for the RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80 https://doi.org/10.1056/NEJMoa012843
  21. Fajadet J, Morice MC, Bode C, Barragan P, Serruys PW, Wijns W, et al. Maintenance of long-term clinical benefit with sirolimuseluting coronary stents: three-year results of the RAVEL trial. Circulation 2005;111:1040-4 https://doi.org/10.1161/01.CIR.0000156334.24955.B2
  22. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al, for the SIRIUS Investigators. Sirolimuseluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23 https://doi.org/10.1056/NEJMoa035071
  23. Schampaert E, Cohen EA, Schluter M, Reeves F, Traboulsi M, Title LM, et al, for the C-SIRIUS Investigators. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004;43:1110-15 https://doi.org/10.1016/j.jacc.2004.01.024
  24. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, et al, for the E-SIRIUS Investigators. Sirolimuseluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362:1093-9 https://doi.org/10.1016/S0140-6736(03)14462-5
  25. Sousa JE, Costa MA, Abizaid A, Sousa AG, Feres F, Mattos LA, et al. Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2003;107:24-7 https://doi.org/10.1161/01.CIR.0000047063.22006.41
  26. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al, for the TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31 https://doi.org/10.1056/NEJMoa032441
  27. Zahn R, Schiele R, Schneider S, Gitt AK, Wienbergen H, Seidl K, et al, for the Maximal Individual Therapy in Acute Myocardial Infarction (MITRA) and the Myocardil Infarction Registry (MIR) Study Groups. Primary angioplasty versus intravenous thrombolysis in acute myocardial infarction: can we define subgroups of patients benefiting most from primary angioplasty? Results from the pooled data of the Maximal Individual Therapy in Acute Myocardial Infarction Registry and the Myocardial Infarction Registry. J Am Coll Cardiol 2001;37:1827-35 https://doi.org/10.1016/S0735-1097(01)01264-5
  28. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003;361:13-20 https://doi.org/10.1016/S0140-6736(03)12113-7
  29. Dalby M, Bouzamondo A, Lechat P, Montalescot G. Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction: a meta-analysis. Circulation 2003;108:1809-14 https://doi.org/10.1161/01.CIR.0000091088.63921.8C
  30. Cannon CP, Gibson CM, Lambrew CT, Shoultz DA, Levy D, French WJ, et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 2000;283:2941-7 https://doi.org/10.1001/jama.283.22.2941
  31. Giugliano RP, Braunwald E. Selecting the best reperfusion strategy in ST-elevation myocardial infarction: it's all a matter of time. Circulation 2003;108:2828-30 https://doi.org/10.1161/01.CIR.0000106684.71725.98
  32. De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation 2004;109:1223-5 https://doi.org/10.1161/01.CIR.0000121424.76486.20
  33. Berger PB, Ellis SG, Holmes DR Jr, Granger CB, Criger DA, Betriu A, et al, for the GUSTO-II Investigators. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. Circulation 1999;100: 14-20 https://doi.org/10.1161/01.CIR.100.1.14
  34. Nallamothu BK, Bates ER. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything? Am J Cardiol 2003;92:824-6 https://doi.org/10.1016/S0002-9149(03)00891-9
  35. Nallamothu BK, Bates ER, Herrin J, Wang Y, Bradley EH, Krumholz HM, for the NRMI Investigators. Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 analysis. Circulation 2005;111:761-7
  36. Morrison LJ, Verbeek PR, McDonald AC, Sawadsky BV, Cook DJ. Mortality and prehospital thrombolysis for acute myocardial infarction: A meta-analysis. JAMA 2000;283:2686-92 https://doi.org/10.1001/jama.283.20.2686
  37. Danchin N, Blanchard D, Steg PG, Sauval P, Hanania G, Goldstein P, et al, for the USIC 2000 Investigators. Impact of prehospital thrombolysis for acute myocardial infarction on 1-year outcome: results from the French Nationwide USIC 2000 Registry. Circulation 2004;110:1909-15 https://doi.org/10.1161/01.CIR.0000143144.82338.36
  38. Steg PG, Bonnefoy E, Chabaud S, Lapostolle F, Dubien PY, Cristofini P, et al, for the Comparison of Angioplasty and Prehospital Thrombolysis In acute Myocardial infarction (CAPTIM) Investigators. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation 2003;108:2851-6 https://doi.org/10.1161/01.CIR.0000103122.10021.F2